IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-7.62%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$297M
AUM Growth
-$31.7M
Cap. Flow
-$5.36M
Cap. Flow %
-1.8%
Top 10 Hldgs %
47.78%
Holding
70
New
9
Increased
18
Reduced
13
Closed
5
Avg Time Held
1.8 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.7 years

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$11M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.45M
3
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$8.21M
4
BIIB icon
Biogen
BIIB
+$7.81M
5
GILD icon
Gilead Sciences
GILD
+$6.85M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
2
APLS icon
Apellis Pharmaceuticals
APLS
+$11.8M
3
AMGN icon
Amgen
AMGN
+$9.48M
4
HRMY icon
Harmony Biosciences
HRMY
+$8.89M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AMGN icon
1
Amgen
AMGN
$230B
$21.3M 7.17%
79,246
-38,000
-32% -$9.48M
2018 Q4
19 quarters
INCY icon
2
Incyte
INCY
$22.6B
$20.7M 6.97%
358,454
– –
2016 Q4
27 quarters
GILD icon
3
Gilead Sciences
GILD
$190B
$17.5M 5.9%
233,584
+89,000
+62% +$6.85M
2016 Q4
27 quarters
ITCI icon
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$16.5M 5.57%
317,856
+141,000
+80% +$8.21M
2020 Q1
14 quarters
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$10.7B
$13.6M 4.58%
153,656
+95,000
+162% +$8.45M
2016 Q4
27 quarters
SUPN icon
6
Supernus Pharmaceuticals
SUPN
$2.34B
$11.8M 3.96%
426,500
-97,000
-19% -$2.95M
2021 Q2
9 quarters
VERA icon
7
Vera Therapeutics
VERA
$1.93B
$10.4M 3.5%
758,355
-216,872
-22% -$3.72M
2021 Q4
7 quarters
BIIB icon
8
Biogen
BIIB
$34.4B
$10.3M 3.48%
40,200
+29,200
+265% +$7.81M
2022 Q2
5 quarters
HRMY icon
9
Harmony Biosciences
HRMY
$2.18B
$10.3M 3.47%
314,500
-256,000
-45% -$8.89M
2021 Q2
9 quarters
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.4M 3.17%
216,000
-44,000
-17% -$1.57M
2019 Q1
18 quarters
RARE icon
11
Ultragenyx Pharmaceutical
RARE
$1.47B
$8.91M 3%
250,052
+170,000
+212% +$6.74M
2021 Q1
10 quarters
QURE icon
12
uniQure
QURE
$1.45B
$8.33M 2.81%
1,241,500
+1,226,000
+7,910% +$11M
2019 Q2
17 quarters
AUPH icon
13
Aurinia Pharmaceuticals
AUPH
$2.21B
$8.07M 2.72%
1,040,530
+467,000
+81% +$4.57M
2020 Q3
12 quarters
UTHR icon
14
United Therapeutics
UTHR
$23.2B
$7.66M 2.58%
33,959
-18,800
-36% -$4.33M
2022 Q1
6 quarters
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$126B
$7.3M 2.46%
21,000
– –
2023 Q1
2 quarters
REGN icon
16
Regeneron Pharmaceuticals
REGN
$80.1B
$7.28M 2.45%
8,847
-18,153
-67% -$14.3M
2020 Q2
13 quarters
ILMN icon
17
Illumina
ILMN
$41B
$6.93M 2.34%
51,914
– –
2021 Q3
8 quarters
ALNY icon
18
Alnylam Pharmaceuticals
ALNY
$30B
$6.52M 2.2%
36,800
-44,800
-55% -$8.55M
2017 Q3
24 quarters
AMLX icon
19
Amylyx Pharmaceuticals
AMLX
$3.39B
$5.4M 1.82%
295,000
+270,000
+1,080% +$5.71M
2023 Q2
1 quarter
KRYS icon
20
Krystal Biotech
KRYS
$9.79B
$5.34M 1.8%
46,092
+147
+0.3% +$17.9K
2021 Q4
7 quarters
KRTX icon
21
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.16M 1.74%
30,500
+4,800
+19% +$903K
2023 Q1
2 quarters
AXSM icon
22
Axsome Therapeutics
AXSM
$8.5B
$4.07M 1.37%
58,300
– –
2023 Q2
1 quarter
ERAS icon
23
Erasca
ERAS
$5.14B
$3.79M 1.28%
1,926,000
+500,000
+35% +$1.28M
2023 Q1
2 quarters
ACAD icon
24
Acadia Pharmaceuticals
ACAD
$3.32B
$3.74M 1.26%
179,702
+28,702
+19% +$780K
2022 Q4
3 quarters
RVNC icon
25
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.31M 1.11%
288,726
– –
2022 Q3
4 quarters
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2023 Portfolio in Review

As of Q3 2023, International Biotechnology Trust held 70 positions worth $297M, down 9.6% from $329M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

International Biotechnology Trust's Q3 2023 filing shows 9 new, 18 increased, 13 reduced and 5 closed positions. Its largest new stake was CRISPR Therapeutics: 63,000 shares worth $2.86M. The largest sale was Regeneron Pharmaceuticals, an estimated $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q3 2023 buy was CRISPR Therapeutics: 63,000 shares worth $2.86M.
  • International Biotechnology Trust added most to uniQure in Q3 2023, an estimated $11M increase.
  • International Biotechnology Trust's biggest Q3 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $14.3M.
  • International Biotechnology Trust fully exited Apellis Pharmaceuticals in Q3 2023, selling an estimated $11.8M.
  • International Biotechnology Trust's ten largest holdings make up 48% of its $297M portfolio in Q3 2023.
  • International Biotechnology Trust opened 9 new positions and closed 5 in Q3 2023.
  • International Biotechnology Trust's portfolio value fell 9.6% quarter-over-quarter to $297M.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.